Steris Corp.' s Complaint Handling System, QS Violations Cited By FDA
This article was originally published in The Gray Sheet
Executive Summary
Steris Corporation failed to report or adequately determine the cause of several adverse events involving the Steris System 1 processor and Quick Connect Kit accessories, FDA contends in a Dec. 9 warning letter to the company.
You may also be interested in...
Endoscope public health advisory
Inconsistencies between reprocessing instructions provided by an automated endoscope reprocessessor (AER) manufacturer and the maker of a reusable bronchoscope device apparently led to several incidents in which patients developed serious infections after undergoing a bronchoscope examination, FDA and the Centers for Disease Control and Prevention state in a Sept. 10 public health advisory. In addition, "bronchoscopes were inadequately reprocessed when inappropriate channel connectors were used with the AER," according to the statement
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.